Exhaled Breathing Condensate (EBC) Features and Lung Function Decline in Chinese Adults
The Screening and Confirmation of Protein Markers Which Can Predict the Decline of Lung Function of Chinese Adults in EBC (Exhaled Breathing Condensate )
Chronic obstructive lung disease (COPD) is a worldwide leading and still increasing cause of chronic morbidity and mortality. The important issue of COPD is its delayed diagnosis. Previous studies have found that accelerated loss of forced expiratory volume in 1 second (FEV1.0) in an individual is considered an indicator of developing COPD. This functional predictive system, due to lower sensitivity, is very difficult to discover high-risk population and earlier stage of the disease. The inflammation occurs earlier than the lung function impairment. Therefore, early detection of the inflammation may theoretically predict the occurrence of COPD and thus may guide early intervention.
Proteomics techniques and protein chip techniques provides us high throughput screening method to figure out characteristic inflammatory or metabolic markers of a diseases. It can be used for searching the biomarkers relating to lung function loss. EBC is collected from exhaled gas and is a good non-invasive method for exploring the pathologic process of the airways.
Thus we designed this study to identify potential biomarkers associated with rapid lung function decline. This study is divided into two parts: 1) screening potential biomarkers between stable COPD and healthy individuals; 2) verifying significant biomarkers of first part in a community-based nested case-control population for 2 years.
調査の概要
状態
条件
詳細な説明
Thus we designed this study. This study is divided into two parts: screening target biomarkers and identifying biomarkers.
- The FIRST STEP is a Case-control study to find target biomarkers. 20 COPD patients and 20 controls are to be enrolled in the study and their EBC and blood are collected. Proteomics techniques and protein chip techniques are to be used to screen COPD specific biomarkers in EBC.
- The SECOND STEP is a community-based nested case-control study to make sure whether the significant biomarkers in first part can predict rapid decline of lung function. The study will be a community based, multicenter prospective cohort designed, which including a total of 2,400 study subjects. EBC and blood are collected at the baseline and followed up for two years. Case group is defined as subjects with rapid decline of lung function and new COPD patients. Control group is selected according to 1:1 matching with age and gender.
研究の種類
入学 (予想される)
連絡先と場所
研究連絡先
- 名前:Cheng Zhang, AR, MD
- メール:zhangcheng033@163.com
研究場所
-
-
Beijing
-
Beijing、Beijing、中国、100034
- 募集
- Peking Universtiy First Hospital
-
コンタクト:
- Zhou Tianyu, PHD
- メール:zty2712@hotmail.com
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
The FIRST STEP of study will be a outpatient based case-control study. 20 stable COPD patients and 20 healthy individuals will be recruited.
The SECOND STEP of study will be a community based, multi-center,prospective nested case-control designed, which including a total of 24OO study subjects, it will focus on two different communities, which are Shi Cha Hai community, De Sheng Community in Beijing
説明
1. FIRST STEP:
Case Group:
Inclusion criteria
- age from 40 to 75 year olds; gender is not limited.
- Stable COPD
- Sign the informed consent with willingness of obeying the protocol. Exclusion criteria
- with known other chronic respiratory diseases except COPD (such as asthma, tuberculosis, bronchiectasis, interstitial lung disease, occupational lung diseases, sarcoidosis, lung cancer, et al);
- had been accepted lung lobectomy or transplantation;
- be ill with severe, or uncontrolled systemic diseases other than COPD (such as psychiatry diseases, chronic liver diseases, heart failure, auto-immunity diseases, chronic renal diseases, et al );
- Alcoholism, drug or solvents addition;
- Acute exacerbation COPD patients (AECOPD)
- Control group:
Inclusion criteria According to age (+ / - 5 years), gender and smoking, to match healthy volunteers as the control group.
- age from 40 to 75 year olds; gender is not limited.
- FEV1 /forced vital capacity (FVC)> 70% after inhaling bronchodilators;
- Sign the informed consent with willingness of obeying the protocol. Exclusion criteria
a. with known other chronic respiratory diseases except COPD (such as asthma, tuberculosis, bronchiectasis, interstitial lung disease, occupational lung diseases, sarcoidosis, lung cancer, et al); b. had been accepted lung lobectomy or transplantation; c. be ill with severe, or uncontrolled systemic diseases other than COPD (such as psychiatry diseases, chronic liver diseases, heart failure, auto-immunity diseases, chronic renal diseases, et al ); d. Alcoholism, drug or solvents addition; e. Acute respiratory infection in 4 weeks (rhinitis, pharyngitis, acute tracheobronchitis, pneumonia, etc.)
2.SECOND STEP: nested case-control study Inclusion criteria
- age from 40 to 75 year olds; gender is not limited.
- have been living in the community for more than 1 years and no plan to move in the near 3 years
- FEV1 / FVC > 70% after inhaling bronchodilators;
- Sign the informed consent with willingness of obeying the protocol.
Exclusion criteria
- with known other chronic respiratory diseases except COPD (such as asthma, tuberculosis, bronchiectasis, interstitial lung disease, occupational lung diseases, sarcoidosis, lung cancer, et al);
- had been accepted lung lobectomy or transplantation;
- be ill with severe, or uncontrolled systemic diseases other than COPD (such as psychiatry diseases, chronic liver diseases, heart failure, auto-immunity diseases, chronic renal diseases, et al );
- Alcoholism, drug or solvents addition;
研究計画
研究はどのように設計されていますか?
デザインの詳細
コホートと介入
グループ/コホート |
---|
Stable COPD in STEP1
no intervention
|
Control in STEP 1
no intervention
|
Case group in STEP 2
no intervention
|
Control group in STEP2
no intervention
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Protein biomarkers in EBC predicting rapid decline of lung function
時間枠:4 years
|
The study(second part) is to identify the biomarkers screened from the first step and make sure which is associated with rapid decline of lung function.
The study will be a community based, multicenter prospective cohort designed, which including a total of 2,400 study subjects.
|
4 years
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Protein biomarkers of EBC between COPD patients and healthy individuals
時間枠:1 year
|
The first part of study is to screen target biomarkers.
20 COPD patients and 20 controls are to be enrolled in the study and their EBC are to reserved.
Proteomics techniques and protein chip techniques were used to screening COPD specific biomarkers.
|
1 year
|
Blood biomarkers between COPD patients and healthy individuals
時間枠:1 year
|
Peripheral blood will be collected.
Plasma and PBMC will be extracted and stored respectively.
|
1 year
|
Blood biomarkers predicting rapid decline of lung function
時間枠:4 year
|
Peripheral blood will be collected.
Plasma and PBMC will be extracted and stored respectively.
|
4 year
|
協力者と研究者
捜査官
- 主任研究者:Guangfa Wang, MD, PHD、Peking Universtiy First Hospital
研究記録日
主要日程の研究
研究開始
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。